The second-quarter performance was boosted by strong growth in sales of pediatric combination vaccines. Net sales of Pentacel((R)) (the first 5-in-1 pediatric combination vaccine licensed in the United States in June 2008 against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b) reached euro 83 million for the quarter.
Net sales of seasonal influenza vaccines rose by 3.3% to euro 32 million.
In May 2009, the U.S. Food and Drug Administration licensed the new sanofi pasteur influenza vaccine manufacturing facility in Swiftwater where production of influenza vaccines has already begun. This facility, representing an investment of $150 million, will produce 100 million doses per year when operating at full capacity. It will take the Group's total production capacity in the United States to 150 million doses of trivalent seasonal influenza vaccine per year.
Sanofi Pasteur received several orders to produce a vaccine against the new A(H1N1) influenza strain, including two contracts from the U.S. Department of Health and Human Services as well as a contract from the French government. Sanofi Pasteur is in discussion with several other governments and announced last June its intent to donate 100 million doses of influenza vaccine to the World Health Organization to help developing countries face the influenza pandemic.
Net sales of Menactra((R)) (quadrivalent meningococcal meningitis vaccine) were up 2.5% at euro 110 million. Filing of Menactra((R)) Infant/Toddler 9 to 12 months in the United States is scheduled for the second half of 200
Copyright©2009 PR Newswire.
All rights reserved